机构：[1]Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.[2]Clinical Research Center of Obstetrics and Gynecology, Jiangsu Key Laboratory of Clinical Immunology of Soochow University, Suzhou, China.[3]Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.[4]Affiliated Hospital of Medical School, Nanjing University, Nanjing Stomatological Hospital, Nanjing, China.[5]Department of Gynecology and Obstetrics, West China Second Hospital, University of Sichuan, Chengdu, China.[6]Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, University of Sichuan, Chengdu, China.
Ovarian cancer (OC) is the most lethal gynecological tumor, characterized by its insidious and frequently recurring metastatic progression. Owing to limited early screening methods, over 70% of OC cases are diagnosed at advanced stages, typically stage III or IV. Recently, N6-methyladenosine (m6A) modification has emerged as a hotspot of epigenetic research, representing a significant endogenous RNA modification in higher eukaryotes. Numerous studies have reported that m6A-related regulatory factors play pivotal roles in tumor development through diverse mechanisms. Moreover, recent studies have indicated the aberrant expression of multiple regulatory factors in OC. Therefore, this paper comprehensively reviews research advancements concerning m6A in OC, aiming to elucidate the regulatory mechanism of m6A-associated regulators on pivotal aspects, such as proliferation, invasion, metastasis, and drug resistance, in OC. Furthermore, it discusses the potential of m6A-associated regulators as early diagnostic markers and therapeutic targets, thus contributing to the diagnosis and treatment of OC.
基金：
The present study was supported by the grants from the Project of Suzhou
Science and Technology Development Plan (No. SLJ202006), the
Project of Jiangsu Health Development Research Center (No.
JSHD2022067), as well as the Fundamental Research Funds for
Soochow University (No. H230337)
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.[2]Clinical Research Center of Obstetrics and Gynecology, Jiangsu Key Laboratory of Clinical Immunology of Soochow University, Suzhou, China.[3]Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.[3]Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.[5]Department of Gynecology and Obstetrics, West China Second Hospital, University of Sichuan, Chengdu, China.[6]Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, University of Sichuan, Chengdu, China.[*1]Department of Gynecology and Obstetrics, West China Second Hospital, University of Sichuan, Sichuan, Chengdu, China[*2]Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Jiangsu, Suzhou, China[*3]Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Jiangsu, Suzhou, China
推荐引用方式(GB/T 7714)：
Zhang Yuhong,Ling Yufeng,Zhou Ying,et al.Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer[J].Cancer Control : Journal Of The Moffitt Cancer Center.2024,31:10732748241256819.doi:10.1177/10732748241256819.
APA：
Zhang Yuhong,Ling Yufeng,Zhou Ying,Shi Xiu,Shen Fangrong...&Wang Juan.(2024).Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.Cancer Control : Journal Of The Moffitt Cancer Center,31,
MLA：
Zhang Yuhong,et al."Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer".Cancer Control : Journal Of The Moffitt Cancer Center 31.(2024):10732748241256819
